Results

Total Results: 1,134 records

Showing results for "days".

41. Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Report 1 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-1.pdf
    June 01, 2022 - two were conducted in multiple countries.12, 14 The mean followup for these 15 new studies was 10.35 days … There was also no difference in terms of sustained pain free at 2 days. … Oral, once 3-28 days Significantly more patients treated by lasmiditan 200 mg, or 100 mg reported … increased pain free at 2 hours and 1 day, and sustained pain free at 1 day and 2 days. … reported significantly more pain reduction at 2 hours and sustained pain free at 1 day and 2 days,

42. Data Points 17: Trends in Bariatric Surgery: Trends in bariatric surgery in Medicare beneficiaries (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/bariatric-surgery-trends_research.pdf
    November 01, 2012 - Rehospitalization within 30 days was identified as any admis- sion within 30 days from discharge, except … in the case of OPLAGB, where rehospitalization was identified as any admission within 30 days of the … 30 days (Table 3). … Black patients were more likely to be rehospitalized within 30 days than whites in total (11.4% vs. … Mortality was low—0.5 percent at 30 days and 1.6 percent within 1 year (Table 3).

43. White Paper: Standardized Library of Lumbar Spondylolisthesis Outcome Measures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/white-paper-lumbar-spondylolisthesis.pdf
    March 01, 2021 - All-cause death within 30 days of treatment. … and non- surgical treatment Defined as treatment-related and systemic adverse events occurring ≤ 30 days … • Recurrent disc herniation requiring a new operation • New neurological deficit (unresolved at 30 days … , that result in medical intervention (such as hospitalization or surgical intervention) within 30 days … of treatment Use of opioids 30 days post-treatment is considered an adverse event and is captured

44. White Paper: Standardized Library of Lumbar Spondylolisthesis Outcome Measures (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-lumbar-spondylolisthesis.pdf
    March 01, 2021 - All-cause death within 30 days of treatment. … and non- surgical treatment Defined as treatment-related and systemic adverse events occurring ≤ 30 days … • Recurrent disc herniation requiring a new operation • New neurological deficit (unresolved at 30 days … , that result in medical intervention (such as hospitalization or surgical intervention) within 30 days … of treatment Use of opioids 30 days post-treatment is considered an adverse event and is captured

45. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/mat-retention-strategies-rapid-review-1.pdf
    August 01, 2020 - Opioid agonist treatment (OAT) days - self-reported in the 30 days before 3-, 6- month interviews … of OAT use per 30 follow-up days: 16.4 linkage group vs 6.4 TAU group, P<.01. … (22/28 days) based on participant self-report of the previous 28 days Computer-based education … in 12- week protocol: 83 days intervention group vs 69 days TAU group (p=0.19) KQ2: Not reported … of heroin use, days of cocaine use, and days of criminal activity (however authors suggest the

46. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
    February 01, 2015 - working days. … No Yes No No No No A1 Inventory 5-10 days No N/A No N/A Yes No L1 Inventory 5-15 days No Yes No No … No No No No No A1 Inventory 5-10 days No No No No Key messages L1 Inventory 5-15 days No No No No … Scoping Review 3-5 days List of available evidence. … Rapid Review 7 days or less 1 page narrative summary of evidence.

47. C-Diff-Infections-Surveillance-140925 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/c-diff-infections-surveillance-140925.pdf
    January 01, 2014 - ) days for reinfections (P=0.177). … In patients who acquired AAD, Pro-2 (2.8 days) and Pro-1 (4.1 days) had shorter symptom duration vs … . placebo (6.4 days). … , CDI Standard precautions: 3486 patient days Universal gloving: 4392 patient days No difference … 36-40 days after randomization.

48. Topic 0318 Psychiatric Hospital Discharge NSD FINAL (2)_SJ_Clean-2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND-0376-140408.pdf
    November 06, 2013 - Intervention(s):  Psychiatric hospitalization: ultra-short (1 to 4 days), short (5 to 6), longer ( … 7 to 10 days), and stays beyond 10 days  Transition support services after discharge (e.g., discharge

49. Comparative Effectiveness Review (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - NR/washout 3 days no NA NR Appendix F. Evidence Table1. 01 [1]. … 31-90 days > 90 days ≤ 200 mg >200 mg ≤ 25 mg > 25 mg (A) Naproxen (B) Ibuprofen (C) Other … Duration of NSAID exposure > 7 days. … days. … 90 days, intra-articular corticosteroid into any other joint within 30 days of study entry, or ongoing

50. ADHD Medications and Risk of Serious Coronary Heart Disease in Yough and Middle-Aged Adults (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/adhd-heart-disease-children_research.pdf
    January 01, 2023 - The number of days of drug use per prescription was estimated based on the fill date and days supply … to 7 days of stockpiling of medication. … Person-days greater than 365 days since last days supply were considered remote use. … Non-use referred to those person-days with no prescribed ADHD medication on those days or at any time … , 31-90 days, 91-182 days, 183-365 days, 366+ days).

51. Medicare-Medication-Use Research (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/medicare-medication-use_research.pdf
    April 01, 2014 - Beneficiaries with psychiatric, chronic medical, or psychiatric-medical conditions spent fewer days … in phase compared to 163 and 263 days for the no-diagnosis group. … ), just slightly longer than the medical diagnosis group (124 days). … While those with none of the measured diagnoses had the most time in the catastrophic phase (163 days … (140 days), they were also the least likely to reach this phase.

52. Antibiotics-Respiratory-Infection Clinician (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/antibiotics-respiratory-infection_clinician.pdf
    March 01, 2016 - acute RTIs by 12 to 72 percent (���) and did not increase the rate of adverse consequences, including days … testing reduced overall prescribing by 28 percent (���) but was associated with an increased number of days … of limited activity or missed work or continuing symptoms at 28 days for URTI or LRTI in primary care … combination intervention: OR 0.30 (95% CI, 0.26 to 0.36) 2 RCTs ��� Adverse consequences — Increased days … combination intervention 2 RCTs ��� — No difference in reconsultation, diagnostic testing use, or days

53. Alcohol-Misuse-Drug-Therapy Clinician (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_clinician.pdf
    February 01, 2016 - drinking 19 2,875 Reduced by naltrexone RD: -0.09 (-0.13 to -0.04) 12 ��� Percentage of drinking days … 15 1,992 Reduced by naltrexone WMD: -5.4 (-7.5 to -3.2) NA ��� Percentage of heavy drinking days 6 … heavy drinking 2 615 No difference RD: -0.01 (-0.14 to 0.13) NA ��� Percentage of heavy drinking days … 2 521 Reduced by topiramate WMD: -8.5 (-15.9 to -1.1) NA ��� Percentage of heavy drinking days 2 521 … In most studies, patients abstained for at least 3 days before starting medication.

54. RESPONSE TO REQUEST FOR WORK ASSIGNMENT (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/copd-anticholinergic-medicines_research.pdf
    December 01, 2009 - Patients were followed for up to 547 days. … Patients were followed until they died, had not filled a prescription for 180 days, or 547 days, which … Events occurring within 30 days following index date were not included. … Third, the timeframe for identifying exposure was reduced to 90 days from 180 days in the base case. … During follow-up there were more than 17.1 million person-days of medication exposure.

55. Executive summary_Comparative Effectiveness Review No. 270: Behavioral Interventions for Migraine Prevention (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-270-bimp-executive-summary.pdf
    May 01, 2024 - following interventions that included a CBT component (pooled effect from 10 trials, -1.1 migraine days … relaxation training may result in higher migraine attack frequency than propranolol (1 trial, 1.40 migraine days … attack frequency than a combination of CBT and relaxation training (1 trial, difference in migraine days … relaxation training are likely to result in lower migraine attack frequency (one trial, -1.6 migraine days

56. Acute Treatments for Episodic Migraine: Surveillance Report 3 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-3.pdf
    August 01, 2022 - significantly increased pain free at 2 hours and at 1 day, sustained pain free at 1 day and at 2 days … Oral, once 3-28 days Significantly more patients treated by lasmiditan 200 mg, or 100 mg reported … increased pain free at 2 hours and 1 day, sustained pain free at 1 day and 2 days, and quality of … reported significantly more pain reduction at 2 hours and sustained pain free at 1 day and 2 days, … Electrical current for 30 seconds and no current for the next 15 seconds 90 days Patients treated

57. Heart-Failure-Transition-Care Clinician (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/heart-failure-transition-care_clinician.pdf
    October 01, 2015 - before discharge (including self-care management) and recom- mends a followup visit within 7 to 14 days … of discharge or a telephone followup within 3 days of discharge (or both). … 824 ò 0.78 (0.65 to 0.94) 10 ��� Mortality 8 1693 ò 0.77 (0.60 to 0.997) 33 ��� Number of hospital days … 977 ó 0.81 (0.58 to 1.12) NA ��� Mortality 7 2011 ò 0.74 (0.56 to 0.97) 27 ��� Number of hospital days … 30- day outcomes, few trials assessed the effectiveness of transitional care interventions at 30 days

58. Translation of a C. difficile Treatment Clinical Pathway Into Machine-Readable Clinical Decision Support Artifacts Prototyped for Electronic Health Record Implementation (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-report-translation-c-diff-treatment-clinical-pathway.pdf
    November 01, 2019 - AND metronidazole 500 mg IV Q8H x 14 days. … Q8H x 14 days. … O Metronidazole PO 500 mg, 3x/day, 10 days, OR O Fidaxomicin PO 200mg, 2x day, 10 days, OR  Add …  Vancomycin PO 125 mg Q6H x 10 days  Add C. … 500 mg, IV, Q8H x 14 days  Add C.

59. Carbohydrate-Intake-Prepub-Final-Research-Table-Rct (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/carbohydrate-intake-prepub-final-research-table-rct.xlsx
    May 29, 2025 - table, coin toss, assigned by a remote/call center using these No: Alternation, case record #, birth days … , week days, participant/provider choice, coverage, ability to pay not acceptable.

60. Liver-Cancer-Therapy Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/liver-cancer-therapy_executive.pdf
    May 01, 2013 - ± 1.8 vs. 1.6 days ± 0.3; p<0.01). … ± 1.9, 1.7 days ± 0.4, 2.2 days ± 0.6, respectively; all p<0.01). … vs. 5.9 days; p = 0.26). … vs. 4.7 days; p<0.0001). … Increases in the ALT and LDH levels were observed for 9 days in the TACE group and 4 days for the TACE